PharmaQo Semaglutide 5mg is a research peptide listed in cartridge format for laboratory and scientific research. Semaglutide is classified as a GLP-1 receptor agonist and has been studied in research involving GLP-1 receptor activity and related biological pathways.
| Specification | Details |
| Product Name | Semaglutide 5MG |
| Brand | PharmaQo |
| Form | Cartridge |
| Amount | 5mg |
| Purity | Verified product purity |
| Category | GLP-1 Research Compound |
| Research Use | Laboratory research only |
| Storage | 2°C to 8°C |
| Product Type | Research Peptide |
£89.00
Smart Packaging
Secure Payment
14-Day Returns
Buy Semaglutide Cartridge 5mg by PharmaQo for laboratory and research requirements involving semaglutide and GLP-1 receptor activity.
Semaglutide Cartridge 5mg is considered to be a 5mg semaglutide product presented in a multidose cartridge. The product is indicated for research use only as regards metabolic and weight loss pathway investigations.
Researchers who intend to utilize this product must take into consideration the up-to-date manufacturer data, specifications, batch information, and analytical documents.
Semaglutide is a man-made protein that is used as a GLP-1 receptor agonist. GLP-1 stands for Glucagon-like peptide 1 which is one of the hormones that control glucose metabolism and appetite.
There have been many studies conducted on semaglutide due to its action on the GLP-1 receptors. The approved semaglutide products are used for some specific clinical indications like diabetes, weight management, etc.
The semaglutide is used for research purposes in the field of studying GLP-1 signaling, metabolic control, glucose-induced insulin release, gastrointestinal physiology, and appetite signaling, among others.
It is not always appropriate to make an assumption about the biological activity of a research product being similar to that of an approved product.
Most of the research on semaglutide centers around its linkages with the GLP-1 receptor and metabolic signal transduction.
The GLP-1 receptor is linked to a number of physiological functions such as glucose-stimulated insulin secretion and glucagon secretion regulation. Studies also examine the link between GLP-1 receptor signaling and appetite/energy balance pathways.
Semaglutide has been subject to research in clinical and laboratory studies with metabolic well-being, glycemic control, body weight regulation, and cardiovascular effects. There is approved indication for semaglutide use by FDA; however, it is not appropriate to apply FDA-approved indication to unapproved or research version of the drug.
Semaglutide research also accounts for the relatively long duration of action and pharmacokinetics of the substance.
Semaglutide is one of the glucagon-like peptide-1 receptor agonists. GLP-1 receptor activity is critical to investigations that aim to explore glucose metabolism, appetite, and endocrine physiology.
Semaglutide has been explored in relation to glucose homeostasis and metabolism. Studies involving glucose-insulin secretion, glucagon, gastric mechanisms, and energy balance may be carried out.
GLP-1 signalling plays an important role in appetite regulation and satiety. Semaglutide has thus been widely studied in research related to appetite regulation and body weight.
There is clinical data that suggests that certain semaglutide products approved by FDA have a positive effect on body weight in particular patient groups, but such clinical data should not automatically be extended to a research product.
Semaglutide has been researched in cardiometabolic studies. Certain semaglutide products have cardiovascular indications approved by FDA in particular patient populations.
FDA-approval indications vary between different products and should not be considered as approval/indications for Semaglutide 5 mg Cartridge produced by PharmaQo.
There are various formulations of semaglutide that exist in the market.
A study cartridge that contains 5 mg of semaglutide is not necessarily a semaglutide medicine by default. This is because an approved semaglutide medicine has been formulated in a particular way with indications and label instructions. The FDA has raised a red flag over semaglutide drugs that are unapproved because they lack FDA premarket safety and effectiveness evaluation like the approved products. Hence researchers need to ascertain the exact nature of semaglutide drug they are studying.
Analytical characterisation is crucial when assessing peptide research materials like semaglutide. The researchers must assess existing documents, and where necessary, use analytical data regarding:
Analytical methods for peptide characterisation could include chromatography and mass spectrometry. The suitable analytical technique depends on the research goal and the parameters to be assessed.
Researchers should use the lot-specific data wherever applicable and should not depend on data from the product listing for all lots.
Brand name for Semaglutide 5mg Cartridge is PharmaQo. The latest description of the product states that it is a 5 mg Semaglutide multi-dose pre-filled pen/cartridge, which is used for scientific and metabolic studies.
Semaglutide is a peptide research material and must be stored and handled following current product documentation from the manufacturer.
Laboratory guidelines should include:
Storage conditions can vary depending on the product formulation and presentation. Therefore, researchers must adhere to current manufacturer’s documentation rather than generic recommendations for peptide storage.
This product information is provided for research use only. A research designation does not imply approval for human or veterinary use.
PharmaQo Semaglutide Cartridge is listed to contain 5 mg of semaglutide. It should be verified with the information from the current product label.
Yes. Semaglutide is a GLP-1 receptor agonist drug and has been widely researched for its physiological effects.
The areas of semaglutide research include GLP-1 receptor signalling, glucose metabolism, pathways associated with appetite, energy balance, metabolic physiology, and cardiovascular research.
Researchers studying semaglutide and GLP-1 receptor activity may consult authoritative sources covering:
£41.00
£120.00
£34.00
